SEARCH

SEARCH BY CITATION

3.10 References

  • 1
    Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006; 20: 10951107.
  • 2
    Pozniak AL, Collins S, Coyne KM et al. British HIV Association guidelines for the treatment of TB/HIV co-infection 2009. Available at: http://www.bhiva.org/documents/Guidelines/Treatment%20Guidelines/Current/TreatmentGuidelines2009.pdf (last accessed 14 May 2009).
  • 3
    Miller R, Huang L. Pneumocystis jirovecii infection. Thorax 2004; 59: 731733.
  • 4
    Gottlieb MS, Schroff R, Schanker HM et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 14251431.
  • 5
    Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998; 91: 813820.
  • 6
    Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322: 161165.
  • 7
    Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178: 11261132.
  • 8
    Stansell JD, Osmond DH, Charlebois E et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155: 6066.
  • 9
    Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS 2000; 14: 25592566.
  • 10
    Lyles RH, Chu C, Mellors JW et al. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study. AIDS 1999; 13: 341349.
  • 11
    Katz MH, Greenspan D, Westenhouse J et al. Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992; 6: 95100.
  • 12
    Stansell JD, Huang L. Pneumocystis carinii pneumonia, In: Merle MA, Volberding PA. eds. The Medical Management of AIDS, 5th edn. Philadelphia: Saunders, 1997: 275300.
  • 13
    Miller RF, Millar AB, Weller IV, Semple SJ. Empirical treatment without bronchoscopy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax 1989; 44: 559564.
  • 14
    Baughman RP, Dohn MN, Frame PT. The continuing utility of bronchoalveolar lavage to diagnose opportunistic infection in AIDS patients. Am J Med 1994; 97: 515522.
  • 15
    Sepkowitz KA, Telzak EE, Gold JW et al. Pneumothorax in AIDS. Ann Intern Med 1991; 114: 455459.
  • 16
    Opravil M, Marincek B, Fuchs WA et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1994; 7: 3945.
  • 17
    Rosen MJ, Tow TW, Teirstein AS, Chuang MT, Marchevsky A, Bottone EJ. Diagnosis of pulmonary complications of the acquired immune deficiency syndrome. Thorax 1985; 40: 571575.
  • 18
    Gruden JF, Huang L, Turner J et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. Am J Roentgenol 1997; 169: 967975.
  • 19
    Picard C, Meignan M, Rosso J, Cinotti L, Mayaud C, Revuz J. Technetium-99m DTPA aerosol and gallium scanning in acquired immune deficiency syndrome. Clin Nucl Med 1987; 12: 501506.
  • 20
    Boiselle PM, Tocino I, Hooley RJ et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients: accuracy, distinguishing features, and mimics. J Thorac Imaging 1997; 12: 4753.
  • 21
    Friedman EP, Miller RF, Severn A, Williams IG, Shaw PJ. Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Clin Radiol 1995; 50: 756760.
  • 22
    Smith DE, McLuckie A, Wyatt J, Gazzard B. Severe exercise hypoxaemia with normal or near normal X-rays: a feature of Pneumocystis carinii infection. Lancet 1988; 2: 10491051.
  • 23
    Porter K, Fairley CK, Wall PG et al. AIDS defining diseases in the UK: the impact of PCP prophylaxis and twelve years of change. Int J STD AIDS 1996; 7: 252257.
  • 24
    Stover DE, White DA, Romano PA, Gellene RA. Diagnosis of pulmonary disease in acquired immune deficiency syndrome (AIDS). Role of bronchoscopy and bronchoalveolar lavage. Am Rev Respir Dis 1984; 130: 659662.
  • 25
    Broaddus C, Dake MD, Stulbarg MS et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 102: 747752.
  • 26
    Levine SJ, Kennedy D, Shelhamer JH et al. Diagnosis of Pneumocystis carinii pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis. Am Rev Respir Dis 1992; 146: 838843.
  • 27
    Huang L, Stansell JD. AIDS and the lung. Med Clin North Am 1996; 80: 775801.
  • 28
    Miller RF, Pugsley WB, Griffiths MH. Open lung biopsy for investigation of acute respiratory episodes in patients with HIV infection and AIDS. Genitourin Med 1995; 71: 280285.
  • 29
    Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect 1997; 12: 7078.
  • 30
    Huggett JF, Taylor MS, Kocjan G et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63: 154159.
  • 31
    Larsen HH, Huang L, Kovacs JA et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004; 189: 16791683.
  • 32
    Huang L, Morris A, Limper AH, Beck JMATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3: 655664.
  • 33
    Durand-Joly I, Chabé M, Soula F, Delhaes L, Camus D, Dei-Cas E. Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Med Microbiol 2005; 45: 405410.
  • 34
    Roger PM, Vandenbos F, Pugliese P et al. Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus. Clin Infect Dis 1998; 26: 509510.
  • 35
    Wharton JM, Coleman DL, Wofsy CB et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105: 3744.
  • 36
    Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109: 280287.
  • 37
    Klein NC, Duncanson FP, Lenox TH et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992; 6: 301305.
  • 38
    Benfield T, Atzori C, Miller RF Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr 2008; 48: 6367.
  • 39
    Catterall JR, Potasman I, Remington JS. Pneumocystis carinii pneumonia in the patient with AIDS. Chest 1985; 88: 758762.
  • 40
    Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124: 792802.
  • 41
    Medina I, Mills J, Leoung G et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776782.
  • 42
    Toma E, Thorne A, Singer J et al. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis 1998; 27: 524530.
  • 43
    Bozzette SA, Sattler FR, Chiu J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990; 323: 14511457.
  • 44
    Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113: 1420.
  • 45
    Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990; 323: 15001504.
  • 46
    Hauser PM, Nahimana A, Taffe P, Weber R, Francioli P, Bille J, Rabodonirina M. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. Clin Infect Dis 2010; 51: e28e33.
  • 47
    Kazanjian P, Armstrong W, Hossler PA et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182: 551557.
  • 48
    Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 1998; 351: 16311632.
  • 49
    Crothers K, Beard CB, Turner J et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 2005; 19: 801805.
  • 50
    Alvarez-Martínez MJ, Moreno ASpanish PCP Working Group et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis 2008; 62: 3443.
  • 51
    Navin TR, Beard CB, Huang L et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358: 545549.
  • 52
    Alvarez-Martínez MJ, Miró JM, Valls ME et al. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients. Diagn Microbiol Infect Dis 2010; 68: 6065.
  • 53
    Hughes W, Leoung G, Kramer F et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328: 15211527.
  • 54
    Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64: 12821290.
  • 55
    Smego RA, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161: 15291533.
  • 56
    Rosenberg DM, McCarthy W, Slavinsky J et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 2001; 15: 211214.
  • 57
    Korraa H, Saadeh C. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. South Med J 1996; 89: 272277.
  • 58
    Chan TY. Co-trimoxazole-induced severe haemolysis: the experience of a large general hospital in Hong Kong. Pharmacoepidemiol Drug Saf 1997; 6: 8992.
  • 59
    Reinke CM, Thomas JK, Graves AH. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. J Pharm Technol 1996; 11: 256262; quiz 293–255.
  • 60
    Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985–2006. Clin Infect Dis 2008; 46: 625633.
  • 61
    Miller RF, Allen E, Copas A, Singer M, Edwards SG. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006; 61: 716721.
  • 62
    Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327: 18361841.
  • 63
    Hardy WD, Feinberg J, Finkelstein DM et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327: 18421848.
  • 64
    Wynia MK, Ioannidis JP, Lau J. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates. AIDS 1998; 12: 13171325.
  • 65
    Mallolas J, Zamora L, Gatell JM, Miró JM, Vernet E, Valls ME, Soriano E, SanMiguel JG. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993; 7: 5964.
  • 66
    El-Sadr WM, Luskin-Hawk R, Yurik TM et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999; 29: 775783.
  • 67
    Bozzette SA, Finkelstein DM, Spector SA et al. A randomized trial of 1QQ antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 693699.
  • 68
    El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339: 18891895.
  • 69
    Carr A, Tindall B, Penny R, Cooper DA. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992; 6: 165171.
  • 70
    Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim–sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7: 6571.
  • 71
    Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994; 93: 10011005.
  • 72
    World Health Organization.. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a pulic health approach. Who, Geneva, Switzerland, 2006. Available at http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf (last accessed May 2010).
  • 73
    Zolopa A, Andersen J, Powderly W et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
  • 74
    Wislez M, Bergot E, Antoine M et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164: 847851.
  • 75
    Barry SM, Johnson MA. Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. HIV Med 2001; 2: 123132.
  • 76
    Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344: 168174.
  • 77
    Lopez Bernaldo de Quiros JC, Miro JM, Pena JM et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344: 159167.
  • 78
    Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)Mocroft A, Reiss P et al. Is it safe to discontinue primary Pneumocystis jirovecii pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 2010; 51: 611619.
  • 79
    Cheng CY, Chen MY, Hsieh SM et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2010; 10: 126.
  • 80
    Selwyn PA, Feingold AR, Hartel D et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988; 2: 267272.
  • 81
    Gordin FM, Roediger MP, Girard PM et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178: 630636.
  • 82
    1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 119.
  • 83
    Chaisson RE. Bacterial pneumonia in patients with human immunodeficiency virus infection. Semin Respir Infect 1989; 4: 133138.
  • 84
    Kohli R, Lo Y, Homel P et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43: 9098.
  • 85
    Pedro-Botet ML, Sopena N, Garcia-Cruz A et al. Streptococcus pneumoniae and Legionella pneumophila pneumonia in HIV-infected patients. Scand J Infect Dis 2007; 39: 122128.
  • 86
    Shankar EM, Kumarasamy N, Balakrishnan P et al. Seroprevalence of Mycoplasma pneumoniae in HIV-infected patients using a microparticle agglutination test. J Med Microbiol 2006; 55 (Pt 6): 759763.
  • 87
    Dalhoff K, Maass M. Chlamydia pneumoniae pneumonia in hospitalized patients. Clinical characteristics and diagnostic value of polymerase chain reaction detection in BAL. Chest 1996; 110: 351356.
  • 88
    Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42: 647656.
  • 89
    Diep BA, Chambers HF, Graber CJ et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148: 249257.
  • 90
    Donisi A, Suardi MG, Casari S et al. Rhodococcus equi infection in HIV-infected patients. AIDS 1996; 10: 359362.
  • 91
    Pintado V, Gomez-Mampaso E, Cobo J et al. Nocardial infection in patients infected with the human immunodeficiency virus. Clin Microbiol Infect 2003; 9: 716720.
  • 92
    Falco V, Fernandez de Sevilla T, Alegre J et al. Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes. Eur Respir J 1994; 7: 235239.
  • 93
    Feldman C, Klugman KP, Yu VL et al. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect 2007; 55: 125135.
  • 94
    Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007: 44: (Suppl. 2): S27–S72.
  • 95
    Woodhead M, Blasi F, Ewig S et al. for the European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 11381180.
  • 96
    Macfarlane JT, Boswell T, Douglas G et al. BTS Guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (Suppl. 4): 164.
  • 97
    Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what's new? Thorax 2004; 59: 364366.
  • 98
    Department of Health. Immunisation against Infectious Disease . http://www.dh.gov.uk/en/Publichealth/Healthprotection/Immunisation/Greenbook/DH_4097254 (last accessed January 2011).
  • 99
    Geretti AMon behalf of the BHIVA Immunization Writing Committee. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795848.
  • 100
    Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162: 6467.
  • 101
    Wasser L, Talavera W. Pulmonary cryptococcosis in AIDS. Chest 1987; 92: 692695.
  • 102
    Meyohas MC, Roux P, Bollens D et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995; 21: 628633.
  • 103
    Chechani V, Kamholz SL. Pulmonary manifestations of disseminated cryptococcosis in patients with AIDS. Chest 1990; 98: 10601066.
  • 104
    Suster B, Akerman M, Orenstein M, Wax MR. Pulmonary manifestations of AIDS: review of 106 episodes. Radiology 1986; 161: 8793.
  • 105
    Torre D, Martegani R, Speranza F, Zeroli C, Fiori GP. Pulmonary cryptococcosis presenting as pneumothorax in a patient with AIDS. Clin Infect Dis 1995; 21: 15241525.
  • 106
    Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. Am Rev Respir Dis 1992; 145: 12261229.
  • 107
    Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994; 19 (Suppl. 1): S41S48.
  • 108
    Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114: 251262.
  • 109
    Kemper CA, Hostetler JS, Follansbee SE et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993; 17: 344352.
  • 110
    Staples CA, Kang EY, Wright JL, Phillips P, Muller NL. Invasive pulmonary aspergillosis in AIDS: radiographic, CT, and pathologic findings. Radiology 1995; 196: 409414.
  • 111
    Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 16041610.
  • 112
    Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 23662367.
  • 113
    Herbrecht R, Denning DWInvasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408415.
  • 114
    Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 15631571.
  • 115
    Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 212.
  • 116
    Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 (Suppl. 3): S265S280.
  • 117
    Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007; 55: 287299.
  • 118
    Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288296.
  • 119
    Hasse B, Strebel B, Thurnheer R, Uhlmann F, Krause M. Chronic necrotizing pulmonary aspergillosis after tuberculosis in an HIV-positive woman: an unusual immune reconstitution phenomenon? AIDS 2005; 19: 21792181.
  • 120
    Rodriguez-Barradas MC, Stool E, Musher DM et al. Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Clin Infect Dis 1996; 23: 7681.
  • 121
    Waxman AB, Goldie SJ, Brett-Smith H, Matthay RA. Cytomegalovirus as a primary pulmonary pathogen in AIDS. Chest 1997; 111: 128134.
  • 122
    Salomon N, Gomez T, Perlman DC, Laya L, Eber C, Mildvan D. Clinical features and outcomes of HIV-related cytomegalovirus pneumonia. AIDS 1997; 11: 319324.
  • 123
    McGuinness G, Scholes JV, Garay SM, Leitman BS, McCauley DI, Naidich DP. Cytomegalovirus pneumonitis: spectrum of parenchymal CT findings with pathologic correlation in 21 AIDS patients. Radiology 1994; 192: 451459.
  • 124
    Jacobson MA, Mills J, Rush J et al. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis 1991; 144: 69.
  • 125
    Bozzette SA, Arcia J, Bartok AE et al. Impact of Pneumocystis carinii and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. J Infect Dis 1992; 165: 9398.
  • 126
    Uberti-Foppa C, Lillo F, Terreni MR et al. Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease. Chest 1998; 113: 919923.
  • 127
    Millar AB, Patou G, Miller RF et al. Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger? Am Rev Respir Dis 1990; 141: 14741477.
  • 128
    Farthing C, Anderson MG, Ellis ME, Gazzard BG, Chanas AC. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. J Med Virol 1987; 22: 157162.
  • 129
    Wohl DA, Zeng D, Stewart P et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 2005; 38: 538544.
  • 130
    Miller RF, Shaw PJ, Williams IG. Immune reconstitution CMV pneumonitis. Sex Transm Infect 2000; 76: 60.
  • 131
    Fine AD, Bridges CB, De Guzman AM et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001; 32: 17841791.
  • 132
    Boschini A, Longo B, Caselli F et al. An outbreak of influenza in a residential drug-rehabilitation community. J Med Virol 2006; 78: 12181222.
  • 133
    Madhi SA, Ramasamy N, Bessellar TG, Saloojee H, Klugman KP. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002; 21: 291297.
  • 134
    Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 17081719.
  • 135
    Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 18451850.
  • 136
    Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337: 874880.
  • 137
    Health Protection Agency.. Pharmacological treatment and prophylaxis of influenza. Version 1.7 12 January 2011. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287147812045 (last accessed January 2011).
  • 138
    Alonso M, Rodríguez-Sánchez B, Giannella M et al. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol 2010; 50: 114118.
  • 139
    Centers for Disease Control and Prevention (CDC). Update: influenza activity–United States, September 28, 2008–January 31, 200. MMWR Morb Mortal Wkly Rep 2009; 58: 115119.
  • 140
    van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363: 13811382.
  • 141
    Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 2009; 48: 12541256.
  • 142
    Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115: 13311342.
  • 143
    Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212217.
  • 144
    Department of Health. Clinical guidelines for patients with an influenza like illness during an influenza pandemic. 2006. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4121753 (last accessed January 2011).
  • 145
    Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430433.
  • 146
    Radwan HM, Cheeseman SH, Lai KK, Ellison III RT. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin Infect Dis 2000; 31: 604606.
  • 147
    Evans KD, Kline MW. Prolonged influenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995; 14: 332334.
  • 148
    Feiterna-Sperling C, Edelmann A, Nickel R et al. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. Clin Infect Dis 2010; 51: e90e94.
  • 149
    Dunleavy A, Lipman M, Miller R Infection in the HIV compromised host, In:Maskell N, Millar A. eds. Oxford Desk Reference Respiratory Medicine. Oxford: Oxford University Press 2009, 210217..